Department of Laboratory Medicine, University of Washington, Seattle, Washington, USA.
Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington, USA.
Sci Rep. 2018 Jun 12;8(1):8989. doi: 10.1038/s41598-018-27224-4.
There are many emerging and re-emerging globally prevalent viruses for which there are no licensed vaccines or antiviral medicines. Arbidol (ARB, umifenovir), used clinically for decades in several countries as an anti-influenza virus drug, inhibits many other viruses. In the current study, we show that ARB inhibits six different isolates of Zika virus (ZIKV), including African and Asian lineage viruses in multiple cell lines and primary human vaginal and cervical epithelial cells. ARB protects against ZIKV-induced cytopathic effects. Time of addition studies indicate that ARB is most effective at suppressing ZIKV when added to cells prior to infection. Moreover, ARB inhibits pseudoviruses expressing the ZIKV Envelope glycoprotein. Thus, ARB, a broadly acting anti-viral agent with a well-established safety profile, inhibits ZIKV, likely by blocking viral entry.
有许多新兴和再现的全球流行病毒,目前还没有获得许可的疫苗或抗病毒药物。阿比多尔(ARB,盐酸吗啉胍),在几个国家临床应用数十年,作为一种抗流感病毒药物,它可以抑制许多其他病毒。在本研究中,我们表明 ARB 抑制了六种不同的寨卡病毒(ZIKV)分离株,包括在多种细胞系和原代人阴道和宫颈上皮细胞中的非洲和亚洲谱系病毒。ARB 可预防寨卡病毒引起的细胞病变效应。添加时间研究表明,ARB 在感染前添加到细胞中时,对抑制 ZIKV 最为有效。此外,ARB 抑制表达寨卡病毒包膜糖蛋白的假病毒。因此,ARB 是一种具有广泛作用的抗病毒药物,具有良好的安全性,可抑制 ZIKV,可能通过阻断病毒进入。